Colorado Medicaid is the third
federally-funded insurance plan to recognize the REN wearable as
safe, effective migraine relief for adolescents and adults ages 12
years and older
BRIDGEWATER, N.J. and
NETANYA, Israel,
July 10,
2024 /PRNewswire/ -- Theranica, a
neuromodulation therapeutics company, today announced Health First
Colorado - Colorado Medicaid's coverage of the
Nerivio® REN wearable, the FDA-cleared, non-drug,
non-disruptive treatment for both acute attacks and prevention of
migraine with or without aura in adolescents and adults ages 12 and
older. This coverage expands access to 1.7 million members,
offering an alternative or supplemental treatment to prescription
and over-the-counter medications.
Colorado Medicaid now covers the Nerivio
REN wearable for effective migraine relief for those ages 12 years
and older.
Migraine disease is complex and non-curable, affecting 14% of
the population, including 100 million adolescents. The majority of
prescription medications for treating and preventing migraine are
not indicated for adolescents. The Nerivio REN wearable triggers
the brain's natural power to address migraine pain and associated
symptoms without drugs or disruption, providing a safe, drug-free,
and non-disruptive option for underserved patient
populations.
Research has shown that early therapeutic intervention may
halt or limit migraine progression and disability. There is
evidence suggesting that many adults with chronic or refractory
migraine developed their migraine as children or adolescents and
may not have been treated with adequate therapies in their
adolescent years.
"Controlling migraine in general, and especially in adolescents
before they transition into adulthood is important to prevent
long-term negative consequences and chronification," said Dr.
Marius Birlea, a neurologist at the
University of Colorado Hospital.
"Colorado Medicaid's coverage of the REN wearable addresses a
pressing need to change the standard of care for migraine and add a
treatment option without drugs. This need is even more critical
when considering adolescents who live with migraine, where we have
to be twice as careful before putting them on a drug."
Colorado Medicaid serves approximately 25% of Coloradans and
this decision continues to build a foundation for commercial
insurance providers and other federally-funded programs to follow.
Earlier this year, Highmark Inc., Blue Cross Blue Shield North
Dakota, and DC Medicaid announced coverage for the Nerivio REN
wearable, leading the effort to provide effective, drug-free
migraine treatments to their members.
"Colorado Medicaid's decision to cover the Nerivio REN wearable
demonstrates their commitment to the well-being of its members,
especially the younger ones," said Alon
Ironi, CEO of Theranica. "Migraine treatment options for the
adolescent age group across the U.S. are limited, leaving many
patients with an urgent unmet need to cope with this debilitating
neurological disorder. We are thrilled that more Americans, and
first and foremost adolescents, will now have access to the REN
wearable as a treatment option. We look forward to having the other
health insurance organizations in Colorado match this important benefit and
update their coverage policies accordingly."
Migraine is the second most common reason for missing work
and school in the U.S. In adolescents, the impact of migraine
disease can result in severe and consequential gaps in learning,
inability to participate socially and contribute to mental health
issues.
Dr. Birlea added, "Certain migraine medications, including some
that are indicated for adolescents, have systemic side effects.
When payers acknowledge and cover migraine treatments that have
less side effects that are non-systemic, patients will benefit for
the long-term."
Payers can also benefit when their members include a REN
wearable as part of their migraine treatment plan. According to
a health-economics study, payors may save significant amounts
of money by covering the REN wearable to prevent migraine, through
a drastic reduction of days of acute migraine medication
intake.
For more information about the Nerivio REN wearable and to
download a prescription form, please visit Nerivio.com.
About Nerivio
Controlled by a smartphone app and
self-administered, the Nerivio REN wearable is a complete migraine
care treatment that wraps around the upper arm and uses sub-painful
Remote Electrical Neuromodulation (REN) to activate nociceptive
nerve fibers in the arm. These fibers send signals that trigger a
descending pain management mechanism in the brain called
conditioned pain modulation (CPM), which turns off migraine pain
and associated symptoms without medication. In simpler terms, the
upper arm is stimulated to unleash a natural process in the brain
to abort or relieve migraine headaches and other associated
symptoms. Each treatment lasts 45 minutes and is applied every
other day for prevention or at the start of a migraine attack for
acute treatment.
About Theranica
Theranica is a neuromodulation
therapeutics company dedicated to creating effective, safe,
affordable, low-side-effect therapies for idiopathic pain
conditions. The company's award-winning flagship wearable,
Nerivio®, is the first FDA-cleared prescribed migraine REN wearable
for acute and/or preventive treatment of migraine. Nerivio has been
used in more than 650,000 migraine treatments in the US, including
by adolescents and veterans. Learn more by visiting our
websites, theranica.com and nerivio.com, and following us on
LinkedIn, X (formerly Twitter), Instagram and
Facebook.
#NoMatterWhat
Theranica Contact:
Ronen
Jashek
ronenj@theranica.com
+972-72-390-9750
Media Contact:
Jennifer
Sefakis
Grey Matter Marketing
jennifer@greymattermarketing.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/colorado-medicaids-decision-to-cover-the-nerivio-ren-wearable-expands-access-for-nearly-two-million-americans-to-drug-free-dual-use-migraine-treatment-302192785.html
SOURCE Theranica